In our previous study, we have shown that 15d-PGJ2 inhibited NF-κB in different tumor cells [4] and in this study we therefore compared the effect of 15d-PGJ2 on this pathway in doxorubicin-resistant and non-resistant tumor cells. Here, NFKB1 is linked to neoplasm.